A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

BACKGROUND: Alpelisib in combination with cetuximab showed synergistic anti-tumour activity in head and neck squamous cell carcinoma (HNSCC) models. OBJECTIVES: The recommended phase 2 dose (RP2D) was determined in a phase 1b dose-escalation study. Phase 2 evaluated anti-tumour activity with a rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Razak, Albiruni R. Abdul, Wang, Hung-Ming, Chang, Jang-Yang, Ahn, Myung-Ju, Munster, Pamela, Blumenschein, George, Solomon, Benjamin, Lim, Darren Wan-Teck, Hong, Ruey-Long, Pfister, David, Saba, Nabil F., Lee, Se-Hoon, van Herpen, Carla, Quadt, Cornelia, Bootle, Douglas, Blumenstein, Lars, Demanse, David, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663259/
https://www.ncbi.nlm.nih.gov/pubmed/37875771
http://dx.doi.org/10.1007/s11523-023-00997-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663259/
https://www.ncbi.nlm.nih.gov/pubmed/37875771
http://dx.doi.org/10.1007/s11523-023-00997-z

Ejemplares similares